LivaNova

Join LivaNova at the Pennsylvania State Perfusion Society Annual Meeting, Oct 3-5 in Pittsburgh. Stop by our booth for a demonstration of the Essenz Perfusion System, and attend our interactive hands-on session over breakfast Saturday morning!

Save the date: LivaNova will discuss Q3 2024 financial results on Wednesday, Oct. 30 at 12 p.m. London time (8 a.m. Eastern Time). A live audio webcast will be available at www.livanova.com/events. To listen by telephone, dial 1 833 470 1428 (U.S.) or 1 929 526 1599 (outside the U.S.). The conference call access code is 881946.

Sam Immanuel, Field Clinical Manager, Cardiopulmonary, shares a key question that drives his work: "How can we give the best to the patient when the patient is completely trusting us?" Hear how that patient-first mentality motivates employees across our Cardiopulmonary and Neuromodulation Business Units in the Asia-Pacific region. #WorkThatMatters #WeAreLivaNova

We are grateful for all LivaNova team members, who each bring a unique contribution to our organization. We appreciate every time someone shares their perspectives, invites new ideas, collaborates, fosters trust, and shows commitment to our patients. On this #WorldGratitudeDay, we encourage everyone to take the time to create a moment of connection and tell a colleague you appreciate her/him/them. with @Kellie Gent

Looking for your next job? We’ve just launched a new platform for jobseekers. Learn about our global business and discover our team culture, then search and apply to current vacancies. Find out if you’re a cultural fit, sign up for job alerts, and join the talent pool to get noticed by our recruiters. Why wait? Join us, and do work that matters. https://livn.info/Careers #WeAreHiring #WeAreLivaNova #WorkThatMatters #FollowYourPurpose

What Factors Influence the Timing of Vagus Nerve Stimulation Implantation? The CORE-VNS, a global prospective real-world study of adjunctive VNS Therapy™ in people with drug-resistant epilepsy (DRE), includes the largest number of individuals who received an implantable VNS device with Scheduled Programming. The first analysis, assessing the baseline characteristics of those enrolled, was published recently in the journal Epilepsia Open.  “Designing the CORE-VNS study allowed us to capture contemporary insights into VNS Therapy and by examining patient demographics, implantation factors, and covariates, we hope to optimize further non-drug treatment strategies for people living with DRE” said Gaia Giannicola, PhD, Senior Clinical Project Manager, LivaNova Plc. Findings from the CORE-VNS Registry reveal insights into the timing of implantation of VNS Therapy. The study highlights that VNS is often considered late in the treatment process with a median of 10 years from epilepsy diagnosis and a mean of 7.1 failed anti-seizure medications (ASMs) prior to VNS Therapy implantation. Seizure and epilepsy diagnosis* (e.g., genetic, and immune epilepsies, generalized motor seizures, and combined focal and generalized epilepsies) were found to be associated with the timing of VNS implantation.  “By examining the real-world practice and outcomes of adjunctive VNS Therapy, clinicians who care for people with epilepsy can more promptly consider different treatment options when drug resistance is recognized. Compared to historical data, our analysis found while the time from diagnosis to VNS implantation has decreased, it still may be too long for some DRE patients who can benefit from a VNS Therapy implant,” said Patrick Kwan, the corresponding author of the article and Professor of Neurology at Monash University in Melbourne, Australia. The full publication is available at https://lnkd.in/gGJeGVXu  View Important Safety Information at: https://lnkd.in/dSQ3BYgK  *Not approved in all geographies. Please consult your local labeling for further information.

#EEC2024 was full of opportunities to learn, share, and connect with the community dedicated to empowering patients with epilepsy and advancing care. Our booth was filled with stimulating conversations, and during our symposium we heard from David McCormick MD, Arjune Sen MD PhD, and Gaia Giannicola PhD with the insights into CORE-VNS, emphasizing the crucial role of real-world evidence in complementing clinical trials, empowering patients and physicians to make well-informed treatment decisions. Thank you to everyone who joined us! Stay connected with LivaNova's latest advancements by registering here: https://lnkd.in/geYkx7J2 Important safety information: https://lnkd.in/dFiPaNkh #Epilepsy #VNSTherapy #WeareLivaNova #EEC2024

We are grateful to have an executive team that understands the importance of helping others realize their potential. Our Chief Innovation Officer Ahmet Tezel, PhD shares how he experienced the profound impacts of this mindset during his 35-day journey on The Camino. 

We applaud Asia Pacific Medical Technology Association (APACMed) for collaboratively driving innovation in the medtech industry over the past decade. We look forward to its continued leadership in the future.

Join us at the LivaNova Booth #221 at the 15th European Epilepsy Congress to celebrate 30 years of VNS Therapy™. Discover our quality of life campaign and try out SenTiva™ at our interactive demo stations. We look forward to seeing you! Important safety information: https://lnkd.in/dFiPaNkh #Epilepsy #VNSTherapy #EEC2024